BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
월요일, 9월 14

Ascendis Pharma AS

ASNDNASDAQ
Trade with Public
Trade with Public
$262.65
-0.86-0.33%
마지막 업데이트: Sep 14, 3:24 PM
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Ascendis Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ascendis Pharma (ASND).

Price Target Range — 10 Quarters

Analyst Consensus — 19 Analysts

1S.Buy
18Buy
Consensus RatingBuy# Analysts19Avg. Consensus PT$299Upside to Avg. PT+13.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 2, 2026OppenheimerLeland GershellPT RaiseOutperform$304→$312
Sep 1, 2026Morgan StanleyMaxwell SkorPT CutOverweight$275→$273
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312

Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $304 to $312.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273

Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $275 to $273.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target

Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.
Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Ascendis Pharma, Lowers Price Target to $330

Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $333 to $330.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on Ascendis Pharma, Lowers Price Target to $326

Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $328 to $326.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved